Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES)
Refine
Year of publication
Document Type
- Article (92)
- Preprint (3)
- Conference Proceeding (2)
- Doctoral Thesis (1)
Has Fulltext
- yes (98)
Is part of the Bibliography
- no (98)
Keywords
- Inflammation (4)
- Pre-analytics (3)
- inflammation (3)
- neuropathic pain (3)
- pain (3)
- spinal cord (3)
- Gene Regulation (2)
- Interleukin (2)
- Lipidomics (2)
- MLL (2)
- Metabolomics (2)
- PGE2 (2)
- Pain (2)
- apoptosis (2)
- cytotoxicity (2)
- differentiation (2)
- extracellular matrix (2)
- migration (2)
- prostaglandin (2)
- prostaglandins (2)
- 11q23/MLL rearrangements (1)
- 15-PGDH (1)
- 2-Arachidonoyl glycerol (1)
- 3-hydroxyanthranilic acid (1)
- 5-lipoxygenase (1)
- 5-lipoxygenase; (1)
- ADAM10 (1)
- AF4 (1)
- ARID5B (1)
- Anandamide (1)
- B16 cells (1)
- Best-practice model (1)
- Biglycan (1)
- Biomarker Discovery Study (1)
- Biomarkers & Diagnostic Imaging (1)
- Blood sample handling (1)
- Blood sampling (1)
- CD3 (1)
- CEBPE (1)
- CXCL10 (1)
- CXCL16 (1)
- CXCR3 (1)
- Case management (1)
- Crohn’s disease (1)
- Cyclosporin A (1)
- Cytokines Induction (1)
- DNA G-quadruplex (1)
- DNA pulldown (1)
- DNA-protein-interactions (1)
- Decorin (1)
- Dendritic Cells (1)
- Dendritic cells (1)
- Diabetic nephropathy (1)
- Doubling time (1)
- Endocannabinoid (1)
- Endocannabinoids (1)
- FTY720 (1)
- Fibrosis (1)
- Fingolimod (1)
- Gene/Regulation (1)
- Glomerulonephritis (1)
- HDAC (1)
- HIV-1 (1)
- HODE (1)
- Highwire (1)
- IDO1 (1)
- IKK epsilon (1)
- IKKε (1)
- IKZF1 (1)
- IL-12 (1)
- IL-18 binding protein (1)
- Immunosuppression (1)
- Infant leukemia (1)
- Innate Immunity (1)
- Innate immunity (1)
- Interleukin-1 (1)
- Interleukin-22 (1)
- Interleukin-36 (1)
- Ischemia-reperfusion injury (1)
- K3EDTA plasma sampling (1)
- Kidney disease (1)
- LC-MS-Based Clinical Research (1)
- Lumican (1)
- MLL-Baby (1)
- MLV (1)
- MMP9 (1)
- MRP4 (1)
- MTT (1)
- MYCBP2 (1)
- Macrophage (1)
- Macrophages (1)
- Metabolism (1)
- NADPH oxidase (1)
- NF-кB (1)
- Neuron (1)
- Nuclear factor kappa B (1)
- Nuklearfaktor Kappa B (1)
- Oral anticoagulation (1)
- PAM (1)
- PHR1 (1)
- Plasma (1)
- RNA-templated DNA repair (1)
- RNA/MicroRNA (1)
- Receptors/Nuclear (1)
- S1P lyase (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- SERS (1)
- STAT1 (1)
- Sampling protocol (1)
- Schmerz (1)
- Schmerzforschung (1)
- Serum (1)
- Sphingosine 1-phosphate (1)
- Sphingosine-1-phosphate (1)
- T Cell Biology (1)
- T-bet (1)
- TBK1 (1)
- TEM (1)
- TRP Channels (1)
- Toll-like receptor (1)
- Trafficking (1)
- Ubiquitin Ligase (1)
- Wilms tumor (1)
- acute leukemia (1)
- adipose-derived stem cells (ASCs) (1)
- age (1)
- amlexanox (1)
- analgesics (1)
- antifibrotic therapy (1)
- autoantigen (1)
- autoimmunity (1)
- autophagy (1)
- back pain (1)
- biglycan (1)
- cPLA2 (1)
- cadherin (1)
- calcitriol (1)
- cancer (1)
- cell adhesion (1)
- cell proliferation (1)
- combination therapy (1)
- cortisol (1)
- costimulation (1)
- cyclooxygenase (1)
- decorin (1)
- diabetic nephropathy (1)
- eicosanoids (1)
- epigenetics (1)
- epithelial‐mesenchymal transition (1)
- fibrocytes (1)
- fibromodulin (1)
- fibrosis (1)
- fluorescence confocal laser scanning microscopy (1)
- fluorescent ligand (1)
- flurbiprofen (1)
- genetic rearrangements (1)
- glycosaminoglycan (1)
- growth factor (1)
- histone deacetylase (1)
- human histamine H3 receptor (1)
- hyperalgesia (1)
- idiopathic pulmonary fibrosis (1)
- immunoglobulin superfamily (1)
- infants (1)
- insulitis (1)
- integrin (1)
- interferon-γ (1)
- interleukin-10 (1)
- interleukin-22 (1)
- intervertebral disc (1)
- invasion (1)
- junctional adhesion molecule (1)
- kynureninase (1)
- kynurenine (1)
- labelfree quantitative mass spectrometry (1)
- leukemia; solid tumors (1)
- leukotriene (1)
- linoleic acid metabolites (1)
- lipids inflammatory pain (1)
- lipoproteins (1)
- liver (1)
- liver fibrosis (1)
- lumican (1)
- mPGES-1 (1)
- macrophage (1)
- macrophage polarization (1)
- macrophages (1)
- melanoma (1)
- miRNA let-7e (1)
- microenvironment (1)
- microglia (1)
- mitogenic effects (1)
- nerve injury (1)
- neuroinflammation (1)
- neuropathy (1)
- nociception (1)
- non-classical adhesion molecule (1)
- p38 MAPK (1)
- pain, dorsal root ganglia (1)
- perfusion (1)
- phagocytosis (1)
- pharmacological tool (1)
- podocytes (1)
- polymorphism (1)
- premature transcript termination (1)
- primary tubular cells (1)
- prostaglandin E (1)
- proteoglycan (1)
- reactive oxygen species (1)
- recurrent chromosomal translocations (1)
- selectin (1)
- signal transducer and activator of transcription (1)
- smooth muscle cells (1)
- sphingosine-1-phosphate (1)
- transient receptor potential channels (1)
- treatment outcome (1)
- tryptophan (1)
- tumor growth (1)
- type I interferons (1)
- vascular biology (1)
- дети первого года жизни (1)
- исходы терапии (1)
- острые лейкозы (1)
- перестройки 11q23/MLL (1)
Institute
BACKGROUND: Human SAMHD1 is a triphosphohydrolase that restricts the replication of retroviruses, retroelements and DNA viruses in noncycling cells. While modes of action have been extensively described for human SAMHD1, only little is known about the regulation of SAMHD1 in the mouse. Here, we characterize the antiviral activity of murine SAMHD1 with the help of knockout mice to shed light on the regulation and the mechanism of the SAMHD1 restriction and to validate the SAMHD1 knockout mouse model for the use in future infectivity studies.
RESULTS: We found that endogenous mouse SAMHD1 restricts not only HIV-1 but also MLV reporter virus infection at the level of reverse transcription in primary myeloid cells. Similar to the human protein, the antiviral activity of murine SAMHD1 is regulated through phosphorylation at threonine 603 and is limited to nondividing cells. Comparing the susceptibility to infection with intracellular dNTP levels and SAMHD1 phosphorylation in different cell types shows that both functions are important determinants of the antiviral activity of murine SAMHD1. In contrast, we found the proposed RNase activity of SAMHD1 to be less important and could not detect any effect of mouse or human SAMHD1 on the level of incoming viral RNA.
CONCLUSION: Our findings show that SAMHD1 in the mouse blocks retroviral infection at the level of reverse transcription and is regulated through cell cycle-dependent phosphorylation. We show that the antiviral restriction mediated by murine SAMHD1 is mechanistically similar to what is known for the human protein, making the SAMHD1 knockout mouse model a valuable tool to characterize the influence of SAMHD1 on the replication of different viruses in vivo.
The processing of pain undergoes several changes in aging that affect sensory nociceptive fibers and the endogenous neuronal inhibitory systems. So far, it is not completely clear whether age-induced modifications are associated with an increase or decrease in pain perception. In this study, we assessed the impact of age on inflammatory nociception in mice and the role of the hormonal inhibitory systems in this context. We investigated the nociceptive behavior of 12-month-old versus 6–8-week-old mice in two behavioral models of inflammatory nociception. Levels of TRP channels, and cortisol as well as cortisol targets, were measured by qPCR, ELISA, and Western blot in the differently aged mice. We observed an age-related reduction in nociceptive behavior during inflammation as well as a higher level of cortisol in the spinal cord of aged mice compared to young mice, while TRP channels were not reduced. Among potential cortisol targets, the NF-κB inhibitor protein alpha (IκBα) was increased, which might contribute to inhibition of NF-κB and a decreased expression and activity of the inducible nitric oxide synthase (iNOS). In conclusion, our results reveal a reduced nociceptive response in aged mice, which might be at least partially mediated by an augmented inflammation-induced increase in the hormonal inhibitory system involving cortisol.
Epigenetic marks critically control gene expression and thus the cellular activity state. The functions of many epigenetic modifiers in the vascular system have not yet been studied. We screened for histone modifiers in endothelial cells and observed a fairly high expression of the histone plant homeodomain finger protein 8 (PHF8). Given its high expression, we hypothesize that this histone demethylase is important for endothelial cell function. Overexpression of PHF8 catalyzed the removal of methyl-groups from histone 3 lysine 9 (H3K9) and H4K20, whereas knockdown of the enzyme increased H3K9 methylation. Knockdown of PHF8 by RNAi also attenuated endothelial proliferation and survival. As a functional readout endothelial migration and tube formation was studied. PHF8 siRNA attenuated the capacity for migration and developing of capillary-like structures. Given the impact of PHF8 on cell cycle genes, endothelial E2F transcription factors were screened, which led to the identification of the gene repressor E2F4 to be controlled by PHF8. Importantly, PHF8 maintains E2F4 but not E2F1 expression in endothelial cells. Consistently, chromatin immunoprecipitation revealed that PHF8 reduces the H3K9me2 level at the E2F4 transcriptional start site, demonstrating a direct function of PHF8 in endothelial E2F4 gene regulation. Conclusion: PHF8 by controlling E2F4 expression maintains endothelial function.
The activation and infiltration of polymorphonuclear neutrophils (PMN) are critical key steps in inflammation. PMN-mediated inflammation is limited by anti-inflammatory and pro-resolving mechanisms, including specialized pro-resolving lipid mediators (SPM). We examined the effects of 15-epi-LXA4 on inflammation and the biosynthesis of pro-inflammatory mediators, such as prostaglandins, leukotriene B4 and various hydroxyeicosatetraenoic acids and SPM, in an oxazolone (OXA)-induced hypersensitivity model for dermal inflammation. 15-epi-LXA4 (100 μM, 5 μL subcutaneously injected) significantly (P < 0.05) reduced inflammation in skin, 24 hours after the OXA challenge, as compared to skin treated with vehicle. No significant influence on the biosynthesis of prostaglandins or leukotriene B4 was observed, whereas the level of 15S-hydroxy-eicosatetraenoic acid was significantly (P < 0.05) lower in the skin areas treated with 15-epi-LXA4. In spite of the use of a fully validated analytical procedure, no SPM were detected in the biological samples. To investigate the reason for the lack of analytical signal, we tried to mimic the production of SPM (lipoxins, resolvins, maresin and protectin) by injecting them subcutaneously into the skin of mice and studying the in vivo availability and distribution of the compounds. All analytes showed very little lateral distribution in skin tissue and their levels were markedly decreased (> 95%) 2 hours after injection. However, docosahexaenoic acid derivatives were biologically more stable than SPM derived from arachidonic acid or eicosapentaenoic acid.
Resveratrol shows beneficial effects in inflammation-based diseases like cancer, cardiovascular and chronic inflammatory diseases. Therefore, the molecular mechanisms of the anti-inflammatory resveratrol effects deserve more attention. In human epithelial DLD-1 and monocytic Mono Mac 6 cells resveratrol decreased the expression of iNOS, IL-8 and TNF-α by reducing mRNA stability without inhibition of the promoter activity. Shown by pharmacological and siRNA-mediated inhibition, the observed effects are SIRT1-independent. Target-fishing and drug responsive target stability experiments showed selective binding of resveratrol to the RNA-binding protein KSRP, a central post-transcriptional regulator of pro-inflammatory gene expression. Knockdown of KSRP expression prevented resveratrol-induced mRNA destabilization in human and murine cells. Resveratrol did not change KSRP expression, but immunoprecipitation experiments indicated that resveratrol reduces the p38 MAPK-related inhibitory KSRP threonine phosphorylation, without blocking p38 MAPK activation or activity. Mutation of the p38 MAPK target site in KSRP blocked the resveratrol effect on pro-inflammatory gene expression. In addition, resveratrol incubation enhanced KSRP-exosome interaction, which is important for mRNA degradation. Finally, resveratrol incubation enhanced its intra-cellular binding to the IL-8, iNOS and TNF-α mRNA. Therefore, modulation of KSRP mRNA binding activity and, thereby, enhancement of mRNA degradation seems to be the common denominator of many anti-inflammatory effects of resveratrol.
Background: Hypoxia-inducible factor-1α (HIF-1α) and NF-κB play important roles in the inflammatory response after hemorrhagic shock and resuscitation (H/R). Here, the role of myeloid HIF-1α in liver hypoxia, injury, and inflammation after H/R with special regard to NF-κB activation was studied.
Methods: Mice with a conditional HIF-1α knockout (KO) in myeloid cell-line and wild-type (WT) controls were hemorrhaged for 90 min ( mm Hg) and resuscitated. Controls underwent only surgical procedures.
Results: After six hours, H/R enhanced the expression of HIF-1α-induced genes vascular endothelial growth factor (VEGF) and adrenomedullin (ADM). In KO mice, this was not observed. H/R-induced liver injury in HIF-1α KO was comparable to WT. Elevated plasma interleukin-6 (IL-6) levels after H/R were not reduced by HIF-1α KO. Local hepatic hypoxia was not significantly reduced in HIF-1α KO compared to controls after H/R. H/R-induced NF-κB phosphorylation in liver did not significantly differ between WT and KO.
Conclusions: Here, deleting HIF-1α in myeloid cells and thereby in Kupffer cells was not protective after H/R. This data indicates that other factors, such as NF-κB, due to its upregulated phosphorylation in WT and KO mice, contrary to HIF-1α, are rather key modulators of inflammation after H/R in our model.
Prostaglandin E2 (PGE2) favors multiple aspects of tumor development and immune evasion. Therefore, microsomal prostaglandin E synthase (mPGES-1/-2), is a potential target for cancer therapy. We explored whether inhibiting mPGES-1 in human and mouse models of breast cancer affects tumor-associated immunity. A new model of breast tumor spheroid killing by human PBMCs was developed. In this model, tumor killing required CD80 expression by tumor-associated phagocytes to trigger cytotoxic T cell activation. Pharmacological mPGES-1 inhibition increased CD80 expression, whereas addition of PGE2, a prostaglandin E2 receptor 2 (EP2) agonist, or activation of signaling downstream of EP2 reduced CD80 expression. Genetic ablation of mPGES-1 resulted in markedly reduced tumor growth in PyMT mice. Macrophages of mPGES-1-/- PyMT mice indeed expressed elevated levels of CD80 compared to their wildtype counterparts. CD80 expression in tumor-spheroid infiltrating mPGES-1-/- macrophages translated into antigen-specific cytotoxic T cell activation. In conclusion, mPGES-1 inhibition elevates CD80 expression by tumor-associated phagocytes to restrict tumor growth. We propose that mPGES-1 inhibition in combination with immune cell activation might be part of a therapeutic strategy to overcome the immunosuppressive tumor microenvironment.
Simultaneous and dose dependent melanoma cytotoxic and immune stimulatory activity of betulin
(2015)
Conventional cytostatic cancer treatments rarely result in the complete eradication of tumor cells. Therefore, new therapeutic strategies focus on antagonizing the immunosuppressive activity of established tumors. In particular, recent studies of antigen-loaded dendritic cells (DCs) eliciting a specific antitumor immune response has raised the hopes of achieving the complete elimination of tumor tissue. Genistein, fingolimod and betulin have already been described as active compounds in different types of cancer. Herein, we applied an integrated screening approach to characterize both their cytostatic and their immune-modulating properties side-by-side. As will be described in detail, our data confirmed that all three compounds exerted proapoptotic and antiproliferative activity in different B16 melanoma cell lines to a given extent, as revealed by an MTT assay, CFSE and DAPI staining. However, while genistein and fingolimod also affected the survival of primary bone marrow (BM) derived DCs of C57BL/6 mice, betulin exhibited a lower cytotoxicity for BMDCs in comparison to the melanoma cells. Moreover, we could show for the first time, that only betulin caused a simultaneous, highly specific immune-stimulating activity, as measured by the IL-12p70 release of Toll-like receptor 4-stimulated BMDCs by ELISA, which was due to increased IL-12p35 mRNA expression. Interestingly, the activation of DCs resulted in enhanced T lymphocyte stimulation, indicated by increased IL-2 and IFN-γ production of cytotoxic T cells in spleen cell co-culture assays which led to a decreased viability of B16 cells in an antigen specific model system. This may overcome the immunosuppressive environment of a tumor and destroy tumor cells more effectively in vivo if the immune response is specific targeted against the tumor tissue by antigen-loaded dendritic cells. In summary, cytostatic agents, such as betulin, that simultaneously exhibit immune stimulatory activity may serve as lead compounds and hold great promise as a novel approach for an integrated cancer therapy.
Dendritic cells (DCs) are the cutting edge in innate and adaptive immunity. The major functions of these antigen-presenting cells are the capture, endosomal processing and presentation of antigens, providing them an exclusive ability to provoke adaptive immune responses and to induce and control tolerance. Immature DCs capture and process antigens, migrate towards secondary lymphoid organs where they present antigens to naive T cells in a well-synchronized sequence of procedures referred to as maturation. Indeed, recent research indicated that sphingolipids are modulators of essential steps in DC homeostasis. It has been recognized that sphingolipids not only modulate the development of DC subtypes from precursor cells but also influence functional activities of DCs such as antigen capture, and cytokine profiling. Thus, it is not astonishing that sphingolipids and sphingolipid metabolism play a substantial role in inflammatory diseases that are modulated by DCs. Here we highlight the function of sphingosine 1-phosphate (S1P) on DC homeostasis and the role of S1P and S1P metabolism in inflammatory diseases.
Aims: We have provided evidence in former studies that cytokines (IL-8, TNF alpha, LBP, TGFß) measured in blood correlate negatively with lung function in deltaF508 homozygous patients. GAP junction proteins might be of importance for the influx of blood cells into the lung. Our aim was to assess the relationship between connexin genotypes and cytokines (IL-8, TNF-alpha, LBP, TGFß) in induced sputum and serum, and lung disease.
Methods: 36 patients homozygous for deltaF508 (median age 18 y, m/f 16/20, FEV1(%) 77) were examined. Sequence analysis was performed for genes encoding GAP junction protein alpha 1 (GJA1/connexin 43) and gap junction protein alpha 4 (GJA4/connexin 37). Cytokines were assessed in serum and induced sputum (IS) by chemiluminescence (DPC Biermann, Bad Homburg, Germany) as well as leukocyte counts.
Results: DNA analysis was performed in 35 patients. Whereas GJA1 showed only one rare heterozygous synonymous SNP (rs138386744) in one patient, four common SNPs were detected in GJA4. Two were synonymous changes, but the third variant (rs41266431) predicts an amino acid substitution (GTA → valine, ATA → isoleucine) as well as the fourth SNP (rs1764391: CCC→proline, TCC→serine). For rs41266431 patients with homozygosity for the G variant had higher IL-8 levels (median: 13.3/8.0 pg/ml, p=0.07) in serum as well as leukocytes in sputum (median: 2050/421 /µl p=0.041) than those showing heterozygosity (G/A). In individuals > 30 years lung function (FEV1 41.3/84.83 % predicted, p=0.07) was worse.
Conclusion: SNP rs41266431 seems a promising candidate for further investigations, suggesting GJA4 a potential disease modifying gene.